Multiple System Atrophy (MSA) Therapeutics Market
Market Insights on Multiple System Atrophy (MSA) Therapeutics covering sales outlook, demand forecast & up-to-date key trends
Multiple System Atrophy (MSA) Therapeutics Market by Type, Diagnosis & Region | Forecast 2023 to 2033
Multiple System Atrophy (MSA) Therapeutics Market Outlook (2023 to 2033)
The global Multiple System Atrophy (MSA) Therapeutics Market is currently valued at US$ 137.3 Million in 2023 and is anticipated to expand at a CAGR of 4.4%. Owing to the technological advances in healthcare the market is likely to propel to US$ 211.1 Million by 2033.
“Rapidly growing geriatric population, promising pipeline drugs, and new product launches are likely to drive the growth of the multiple system atrophy (MSA) therapeutics Market in the forecast period.”
|
Report Attribute |
Details |
|
Expected Market Value (2023) |
US$ 137.3Million |
|
Projected Forecast Value (2033) |
US$211.1 Million |
|
Global Growth Rate (2023 to 2033) |
% CAGR |
Multiple system atrophy (MSA) is a neurodegenerative disorder that causes symptoms that affect both the autonomic nervous system and movement. The multiple system atrophy causes are unknown, and most cases are sporadic. The accumulation of alpha-synuclein is a distinguishing feature of MSA.
The slowness of movement, tremors, rigidity, and incoordination are the first signs and multiple system atrophy symptoms. The parkinsonian type (MSA-P) with primary symptoms similar to Parkinson's disease and the cerebellar type (MSA-C) with primary symptoms featuring ataxia is the most prominent multiple system atrophy symptoms of evaluation.
Multiple system atrophy diagnosis is difficult, especially in the early stages, because many of the symptoms are similar to Parkinson's disease. Autonomic testing (such as blood pressure control and heart rate control), assessment of bladder function, and neuroimaging such as an MRI (magnetic resonance imaging) or PET scan are examples of diagnostic tests.
Let us know your requirement to get
100% FREE customization
Multiple System Atrophy(MSA) Therapeutics Market Revenue Analysis 2017 to 2022 vs. Future Outlook 2023 to 2033
The Multiple System Atrophy (MSA) Market is expected to gain market growth in the forecast period of 2023 to 2033. Latest market analysis by FMI the market is to grow at a CAGR of 4.4% in the above-mentioned forecast period.
The Covid-19 pandemic has had a significant effect on the market. The COVID-19 pandemic has relatively little of an impact on the world market for multiple system atrophy (MSA) therapeutics. The epidemic has had a direct influence on the supply and demand of medications, as well as on businesses and financial markets. It has also disturbed the distribution system.
The global multiple system atrophy (MSA) therapeutics markets grew at a CAGR of 4.0% from 2018 to 2022, as per Future Market Insights, a provider of market research and competitive intelligence.
The multiple system atrophy market share is expected to grow significantly, mainly due to increasing cases of neurodegenerative disorders. The multiple system atrophy market is expected to witness advancement in the upcoming years due to a new type of drug launch. Due to patent protection loss, new players are expected to enter the multiple system atrophy during the forecast years.
What are the Key Drivers to the Multiple System Atrophy (MSA) Therapeutics Market?
Increase in the Frequency of Neurodegenerative Diseases, Which Is One of the Primary Reasons Driving the Growth Market
The major market growth factors include the rising prevalence of neurodegenerative disorders, increasing awareness among the global population, and a strong product pipeline for neurological disease treatment. With the increasing global population and an average lifespan, the prevalence of multiple system atrophy is on the rise.
People affected by MSA experience dysfunction of the autonomic nervous system, which commonly manifests as orthostatic hypotension, impotence, loss of sweating, dry mouth and urinary retention, and incontinence.
According to the National Library of Medicine - MSA is considered an orphan disease with an annual incidence rate of 0.1-3 per 100,000 depending on age and geographic region.
Increase in government support and drug approval to widen the market scope.
In addition, increasing government support and increasing awareness about neurodegenerative disorders fuel the market growth. The rise in expenditure on healthcare in developing countries and the growth in patient awareness of the use of nerve monitoring devices provide new opportunities for market players. Awareness regarding the clinical benefits of nerve monitoring drives the sales of multiple system atrophy therapeutics market in the forecasting period.
For instance, in September 2020 - Alterity Therapeutics biotechnology company dedicated to developing disease-modifying treatments for neurodegenerative diseases announced the approval of its Investigational New Drug (IND) application by the US Food and Drug Administration (FDA) to allow evaluation of ATH434 in individuals with Multiple System Atrophy (MSA), a rare and highly debilitating Parkinsonian disorder. The approval of this IND authorizes Alterity to conduct its Phase 2 clinical trial in the US
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystWhich Factors Are Restraining the Growth Multiple System Atrophy Multiple System Atrophy (MSA) Therapeutics Market?
Inadequate reimbursement policies may hamper global market growth.
The lack of government and hospital reimbursement policies for treating neurodegenerative illnesses such as Alzheimer's, Amyotrophic Lateral Sclerosis (ALS), and Parkinson's disease restricts the market growth. On the other hand, patients are switching to generics due to the lower cost, which is expected to limit the use of patented drugs.
The exceptionally high price is expected to stifle market growth by limiting access to quality treatment in middle and low-income countries.
High failure rates in clinical trials and research & development (R&D): Clinical trial and research and development (R&D) failure rates have always been a significant challenge within the multiple system atrophy therapeutics market. Companies are constantly investing in Research and Development to develop treatment options for neurodegenerative diseases, but very few treatments are currently approved.
Which is the Leading Region in the Multiple System Atrophy (MSA) Therapeutics Market?
Growing Prevalence of MSA in Region to Drive the Market Growth
North America accounts for the market share of 45.3% of multiple system atrophy therapeutics in 2023 and is likely to lead the multiple system atrophy market during the forecast period.
Growing medication demand, high prices, increased Research and Development investment, and favorable health reimbursement policies are driving the growth of the multiple system atrophy market in North America.
MSA is affecting potentially 15,000 to 50,000 Americans, including men and women and all racial groups. Symptoms of the disease appear in a person’s 50s and advance rapidly over the course of 5 to 10 years, with progressive loss of motor function and eventual confinement to bed. People with MSA often develop pneumonia in the later stages of the disease and may suddenly die from cardiac or respiratory issues.
A unified Market Research Subscription Platform, built for today's disparate research needs.
Why is the Multiple System Atrophy (MSA) Therapeutics Market in Europe Expected to Be Highly Opportunistic?
Increased R&D Investment and Favourable Health Reimbursement Policies are Driving The Growth of The Market In Europe
Europe is expected to be the most significant neurodegenerative disease market. Factors affecting the growth of the market studied are the increasing number of MSA disorders, and research and development by private and government organizations focused on developing treatments for such diseases.
The growth of the European multiple system atrophy therapeutics market during the forecast period is attributed to an increase in the elderly population, an escalation in healthcare expenditure, and increasing funding from the government. Europe to exhibit a CAGR of 4.2% in the multiple system atrophy therapeutics market during the forecast period.
For instance, in August 2022, Alterity Therapeutics a biotechnology company dedicated to developing disease-modifying treatments for neurodegenerative diseases, today announced the Company’s Phase 2 clinical trial of ATH434 for the treatment of patients with Multiple System Atrophy (MSA) is now open for enrolment in the United Kingdom.
Country-wise Forecast CAGRs for the Multiple System Atrophy (MSA) Therapeutics Market
|
UK |
4.2% |
|
India |
3.8% |
|
South Korea |
4.0% |
|
China |
4.1% |
|
US |
4.4% |
Category wise Insights
Based on Diagnosis, Which Is the Most Prominent Segment in Multiple System Atrophy (MSA) Therapeutics Market?
PET Scan Segment remains dominant among other types
Based on diagnosis multiple system atrophy market is segmented into Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), Single Photon Emission Computed Tomography (SPECT), Tilt Table Test, and Others. Among these, the PET scan segment dominated the market in 2023 with a revenue share of 34.6%.
A PET scan (positron emission tomography, which allows doctors to see how organs and tissues are functioning) is sometimes used to see if the metabolic function is reduced in specific parts of the brain. DaTscan can assess the dopamine transporter in a part of the brain called the striatum and can help physicians determine if the condition is caused by a dopamine system disorder; however, this test cannot differentiate between MSA and Parkinson’s disease. Individuals with MSA typically do not have sustained improvement in their symptoms with levodopa (a drug used to treat Parkinson’s disease), a finding that often supports the diagnosis of MSA.
Start-up Scenario
How do New Entrants Contribute to the Multiple System Atrophy (MSA Therapeutics Market?
With technological innovations happening at a rapid pace, and companies looking for ways to increase customer engagement, start-ups are taking all possible steps to establish a name for themselves in the multiple system atrophy therapeutics market.
Some of the start-ups in the multiple system atrophy therapeutics market include-
- Alterity Therapeutics provides therapies to treat neurodegenerative diseases. The company's lead drug candidate PBT434 is meant for Parkinsonian disorders and is being evaluated in clinical trials. The drug is a small molecule designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has been shown to reduce abnormal accumulation of α-synuclein and tau proteins in animal models of disease by restoring normal iron balance in the brain.
- AFFiRiS is developing therapeutics for neurodegenerative diseases. The technology called antigen-specific peptide vaccines is used for the prevention and treatment of Parkinson's disease, Huntington's disease, and multiple system atrophy among others. The company's proprietary AFFITOME Technology delivers peptides that induce an immune response where the generated antibodies target the proteins. Currently, the company has 7 candidates in the clinical pipeline against Parkinson's, MSA, and Hypercholesterolemia.
- Enterin - Developer of pharmaceuticals that repair the gut-brain axis to treat patients suffering from neurodegenerative diseases. Its lead compound, ENT-01 (kenterin), displaces membrane-bound alpha-synuclein (αS) aggregates from nerve cells in the enteric nervous system (ENS) and improves neural signaling between the gut and the brain in preclinical models of Parkinson’s disease. ENT-01 is being developed to reverse the constipation of Parkinson’s disease, multiple systems atrophy, Schizophrenia, and an Autism spectrum disorder.
- Yada Pharmaceuticals - Developer of drugs for neuropsychological and neurological diseases. The company's lead product candidate RS-D7 is an NCE and NMDA modulator used for the treatment of schizophrenia and multiple systems atrophy.
Competitive Landscape
Biohaven Pharmaceuticals, Inc., Sumitomo Dainippon Pharma Co., Ltd., AstraZeneca plc, Theravance Biopharma, Inc., Merck & Co., Neuropore Therapies Inc, Newron Pharmaceuticals SpA, ProMIS Neurosciences Inc, Stealth BioTherapeutics Corp, Chelsea Therapeutics International, Ltd. are some of the key players in the multiple system atrophy therapeutics industry.
The manufacturers are involved in the production of multiple system atrophy therapeutics in a larger capacity. Research and innovation are also conducted to launch innovative products for multiple system atrophy therapeutics.
Also, some of the key players are acquiring small pharmaceutical companies to increase their production capacity. Suppliers are focusing on expanding their market presence across the world by initiating new product launches and boosting sales.
- In April 2022, ProMIS Neurosciences, Inc. a biotechnology company focused on the discovery and development of potential therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative diseases, announced new milestones in potential therapeutic approaches for ALS.
- In October 2022, Biohaven Ltd. announced advancements in the development of its MoDE extracellular target degrader platform technology licensed from Yale University for various disease indications, including, but not limited to, neurological disorders, cancer, and infectious and autoimmune diseases.
Report Scope
|
Report Attribute |
Details |
|
Growth Rate |
CAGR from 2023 to 2033 |
|
Expected Market Value (2023) |
US$ 137.3 Million |
|
Projected Forecast Value (2033) |
US$ 211.1 Million |
|
Base Year for Estimation |
2022 |
|
Historical Data |
2017 to 2022 |
|
Forecast Period |
2023 to 2033 |
|
Quantitative Units |
Revenue in USD Million & CAGR from 2023 to 2033 |
|
Report Coverage |
Revenue Forecast, Volume Forecast, Company Ranking, Competitive L&scape, Growth Factors, Trends & Pricing Analysis |
|
Segments Covered |
|
|
Regions Covered |
|
|
Key Countries Profiled |
|
|
Key Companies Profiled |
|
|
Customization |
Available Upon Request |
Key Segments Covered in the Multiple System Atrophy (MSA) Market Industry Survey
Multiple System Atrophy (MSA) Therapeutics Market by Type:
- Parkinsonian
- Cerebellar
Multiple System Atrophy (MSA) Therapeutics Market by Diagnosis:
- Magnetic Resonance Imaging (MRI)
- Positron Emission Tomography (PET)
- Single Photon Emission Computed Tomography (SPECT)
- Tilt Table Test
- Others
Multiple System Atrophy (MSA) Therapeutics Market by RegionP:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East & Africa (MEA)
Frequently Asked Questions
What is the expected valuation of the multiple system atrophy therapeutics market?
The global multiple system atrophy therapeutics market is likely to reach a valuation of US$137.3 Million by the end of 2023.
Who are the key players in the multiple system atrophy therapeutics market?
Biohaven Pharmaceuticals, Inc., Sumitomo Dainippon Pharma Co., Ltd., AstraZeneca plc, Theravance Biopharma, Inc., and Merck & Co are some of the key players in the global multiple system atrophy therapeutics market.
What are the future prospects for multiple system atrophy therapeutics market sales?
Sales of the multiple system atrophy therapeutics market are likely to expand at 4.4% CAGR through 2033.
Which are the top 5 countries driving demand for multiple system atrophy therapeutics?
The US, Canada, Japan, China, & Germany are expected to drive most of the demand for the multiple system atrophy therapeutics market.
What will be the global age related molecular degeneration market revenue total by 2033?
By the end of 2033, the global market for multiple system atrophy therapeutics market is predicted to reach a valuation of US$ 211.1 Million
Table of Content
1. Executive Summary | Multiple System Atrophy (MSA) Therapeutics Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Type 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Type, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Type, 2023 to 2033 5.3.1. Parkinsonian 5.3.2. Cerebellar 5.4. Y-o-Y Growth Trend Analysis By Type, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Type, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Diagnosis 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Diagnosis, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Diagnosis, 2023 to 2033 6.3.1. Magnetic Resonance Imaging (MRI) 6.3.2. Positron Emission Tomography (PET) 6.3.3. Single Photon Emission Computed Tomography (SPECT) 6.3.4. Tilt Table Test 6.3.5. Others 6.4. Y-o-Y Growth Trend Analysis By Diagnosis, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Diagnosis, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 7.1. Introduction 7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 7.3.1. North America 7.3.2. Latin America 7.3.3. Europe 7.3.4. South Asia 7.3.5. East Asia 7.3.6. Oceania 7.3.7. Middle East & Africa (MEA) 7.4. Market Attractiveness Analysis By Region 8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 8.2.1. By Country 8.2.1.1. The US 8.2.1.2. Canada 8.2.2. By Type 8.2.3. By Diagnosis 8.3. Market Attractiveness Analysis 8.3.1. By Country 8.3.2. By Type 8.3.3. By Diagnosis 8.4. Key Takeaways 9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 9.2.1. By Country 9.2.1.1. Brazil 9.2.1.2. Mexico 9.2.1.3. Rest of Latin America 9.2.2. By Type 9.2.3. By Diagnosis 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Type 9.3.3. By Diagnosis 9.4. Key Takeaways 10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. Germany 10.2.1.2. The UK 10.2.1.3. France 10.2.1.4. Spain 10.2.1.5. Italy 10.2.1.6. Rest of Europe 10.2.2. By Type 10.2.3. By Diagnosis 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Type 10.3.3. By Diagnosis 10.4. Key Takeaways 11. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. India 11.2.1.2. Malaysia 11.2.1.3. Singapore 11.2.1.4. Thailand 11.2.1.5. Rest of South Asia 11.2.2. By Type 11.2.3. By Diagnosis 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Type 11.3.3. By Diagnosis 11.4. Key Takeaways 12. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. China 12.2.1.2. Japan 12.2.1.3. South Korea 12.2.2. By Type 12.2.3. By Diagnosis 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Type 12.3.3. By Diagnosis 12.4. Key Takeaways 13. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. Australia 13.2.1.2. New Zealand 13.2.2. By Type 13.2.3. By Diagnosis 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Type 13.3.3. By Diagnosis 13.4. Key Takeaways 14. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. GCC Countries 14.2.1.2. South Africa 14.2.1.3. Israel 14.2.1.4. Rest of MEA 14.2.2. By Type 14.2.3. By Diagnosis 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Type 14.3.3. By Diagnosis 14.4. Key Takeaways 15. Key Countries Market Analysis 15.1. The US 15.1.1. Pricing Analysis 15.1.2. Market Share Analysis, 2022 15.1.2.1. By Type 15.1.2.2. By Diagnosis 15.2. Canada 15.2.1. Pricing Analysis 15.2.2. Market Share Analysis, 2022 15.2.2.1. By Type 15.2.2.2. By Diagnosis 15.3. Brazil 15.3.1. Pricing Analysis 15.3.2. Market Share Analysis, 2022 15.3.2.1. By Type 15.3.2.2. By Diagnosis 15.4. Mexico 15.4.1. Pricing Analysis 15.4.2. Market Share Analysis, 2022 15.4.2.1. By Type 15.4.2.2. By Diagnosis 15.5. Germany 15.5.1. Pricing Analysis 15.5.2. Market Share Analysis, 2022 15.5.2.1. By Type 15.5.2.2. By Diagnosis 15.6. The UK 15.6.1. Pricing Analysis 15.6.2. Market Share Analysis, 2022 15.6.2.1. By Type 15.6.2.2. By Diagnosis 15.7. France 15.7.1. Pricing Analysis 15.7.2. Market Share Analysis, 2022 15.7.2.1. By Type 15.7.2.2. By Diagnosis 15.8. Spain 15.8.1. Pricing Analysis 15.8.2. Market Share Analysis, 2022 15.8.2.1. By Type 15.8.2.2. By Diagnosis 15.9. Italy 15.9.1. Pricing Analysis 15.9.2. Market Share Analysis, 2022 15.9.2.1. By Type 15.9.2.2. By Diagnosis 15.10. India 15.10.1. Pricing Analysis 15.10.2. Market Share Analysis, 2022 15.10.2.1. By Type 15.10.2.2. By Diagnosis 15.11. Malaysia 15.11.1. Pricing Analysis 15.11.2. Market Share Analysis, 2022 15.11.2.1. By Type 15.11.2.2. By Diagnosis 15.12. Singapore 15.12.1. Pricing Analysis 15.12.2. Market Share Analysis, 2022 15.12.2.1. By Type 15.12.2.2. By Diagnosis 15.13. Thailand 15.13.1. Pricing Analysis 15.13.2. Market Share Analysis, 2022 15.13.2.1. By Type 15.13.2.2. By Diagnosis 15.14. China 15.14.1. Pricing Analysis 15.14.2. Market Share Analysis, 2022 15.14.2.1. By Type 15.14.2.2. By Diagnosis 15.15. Japan 15.15.1. Pricing Analysis 15.15.2. Market Share Analysis, 2022 15.15.2.1. By Type 15.15.2.2. By Diagnosis 15.16. South Korea 15.16.1. Pricing Analysis 15.16.2. Market Share Analysis, 2022 15.16.2.1. By Type 15.16.2.2. By Diagnosis 15.17. Australia 15.17.1. Pricing Analysis 15.17.2. Market Share Analysis, 2022 15.17.2.1. By Type 15.17.2.2. By Diagnosis 15.18. New Zealand 15.18.1. Pricing Analysis 15.18.2. Market Share Analysis, 2022 15.18.2.1. By Type 15.18.2.2. By Diagnosis 15.19. GCC Countries 15.19.1. Pricing Analysis 15.19.2. Market Share Analysis, 2022 15.19.2.1. By Type 15.19.2.2. By Diagnosis 15.20. South Africa 15.20.1. Pricing Analysis 15.20.2. Market Share Analysis, 2022 15.20.2.1. By Type 15.20.2.2. By Diagnosis 15.21. Israel 15.21.1. Pricing Analysis 15.21.2. Market Share Analysis, 2022 15.21.2.1. By Type 15.21.2.2. By Diagnosis 16. Market Structure Analysis 16.1. Competition Dashboard 16.2. Competition Benchmarking 16.3. Market Share Analysis of Top Players 16.3.1. By Regional 16.3.2. By Type 16.3.3. By Diagnosis 17. Competition Analysis 17.1. Competition Deep Dive 17.1.1. Biohaven Pharmaceuticals, Inc. 17.1.1.1. Overview 17.1.1.2. Product Portfolio 17.1.1.3. Profitability by Market Segments 17.1.1.4. Sales Footprint 17.1.1.5. Strategy Overview 17.1.1.5.1. Marketing Strategy 17.1.2. Sumitomo Dainippon Pharma Co., Ltd. 17.1.2.1. Overview 17.1.2.2. Product Portfolio 17.1.2.3. Profitability by Market Segments 17.1.2.4. Sales Footprint 17.1.2.5. Strategy Overview 17.1.2.5.1. Marketing Strategy 17.1.3. AstraZeneca plc 17.1.3.1. Overview 17.1.3.2. Product Portfolio 17.1.3.3. Profitability by Market Segments 17.1.3.4. Sales Footprint 17.1.3.5. Strategy Overview 17.1.3.5.1. Marketing Strategy 17.1.4. Theravance Biopharma, Inc. 17.1.4.1. Overview 17.1.4.2. Product Portfolio 17.1.4.3. Profitability by Market Segments 17.1.4.4. Sales Footprint 17.1.4.5. Strategy Overview 17.1.4.5.1. Marketing Strategy 17.1.5. Merck & Co. 17.1.5.1. Overview 17.1.5.2. Product Portfolio 17.1.5.3. Profitability by Market Segments 17.1.5.4. Sales Footprint 17.1.5.5. Strategy Overview 17.1.5.5.1. Marketing Strategy 17.1.6. Neuropore Therapies Inc 17.1.6.1. Overview 17.1.6.2. Product Portfolio 17.1.6.3. Profitability by Market Segments 17.1.6.4. Sales Footprint 17.1.6.5. Strategy Overview 17.1.6.5.1. Marketing Strategy 17.1.7. Newron Pharmaceuticals SpA 17.1.7.1. Overview 17.1.7.2. Product Portfolio 17.1.7.3. Profitability by Market Segments 17.1.7.4. Sales Footprint 17.1.7.5. Strategy Overview 17.1.7.5.1. Marketing Strategy 17.1.8. ProMIS Neurosciences Inc 17.1.8.1. Overview 17.1.8.2. Product Portfolio 17.1.8.3. Profitability by Market Segments 17.1.8.4. Sales Footprint 17.1.8.5. Strategy Overview 17.1.8.5.1. Marketing Strategy 17.1.9. Stealth BioTherapeutics Corp 17.1.9.1. Overview 17.1.9.2. Product Portfolio 17.1.9.3. Profitability by Market Segments 17.1.9.4. Sales Footprint 17.1.9.5. Strategy Overview 17.1.9.5.1. Marketing Strategy 17.1.10. Chelsea Therapeutics International, Ltd. 17.1.10.1. Overview 17.1.10.2. Product Portfolio 17.1.10.3. Profitability by Market Segments 17.1.10.4. Sales Footprint 17.1.10.5. Strategy Overview 17.1.10.5.1. Marketing Strategy 18. Assumptions & Acronyms Used 19. Research Methodology
Let us know your requirement to get
100% FREE customization
List of Tables
Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033 Table 2: Global Market Value (US$ Million) Forecast by Type, 2018 to 2033 Table 3: Global Market Value (US$ Million) Forecast by Diagnosis, 2018 to 2033 Table 4: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 5: North America Market Value (US$ Million) Forecast by Type, 2018 to 2033 Table 6: North America Market Value (US$ Million) Forecast by Diagnosis, 2018 to 2033 Table 7: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 8: Latin America Market Value (US$ Million) Forecast by Type, 2018 to 2033 Table 9: Latin America Market Value (US$ Million) Forecast by Diagnosis, 2018 to 2033 Table 10: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 11: Europe Market Value (US$ Million) Forecast by Type, 2018 to 2033 Table 12: Europe Market Value (US$ Million) Forecast by Diagnosis, 2018 to 2033 Table 13: South Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 14: South Asia Market Value (US$ Million) Forecast by Type, 2018 to 2033 Table 15: South Asia Market Value (US$ Million) Forecast by Diagnosis, 2018 to 2033 Table 16: East Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 17: East Asia Market Value (US$ Million) Forecast by Type, 2018 to 2033 Table 18: East Asia Market Value (US$ Million) Forecast by Diagnosis, 2018 to 2033 Table 19: Oceania Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 20: Oceania Market Value (US$ Million) Forecast by Type, 2018 to 2033 Table 21: Oceania Market Value (US$ Million) Forecast by Diagnosis, 2018 to 2033 Table 22: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 23: MEA Market Value (US$ Million) Forecast by Type, 2018 to 2033 Table 24: MEA Market Value (US$ Million) Forecast by Diagnosis, 2018 to 2033
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 1: Global Market Value (US$ Million) by Type, 2023 to 2033 Figure 2: Global Market Value (US$ Million) by Diagnosis, 2023 to 2033 Figure 3: Global Market Value (US$ Million) by Region, 2023 to 2033 Figure 4: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033 Figure 5: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033 Figure 6: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033 Figure 7: Global Market Value (US$ Million) Analysis by Type, 2018 to 2033 Figure 8: Global Market Value Share (%) and BPS Analysis by Type, 2023 to 2033 Figure 9: Global Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033 Figure 10: Global Market Value (US$ Million) Analysis by Diagnosis, 2018 to 2033 Figure 11: Global Market Value Share (%) and BPS Analysis by Diagnosis, 2023 to 2033 Figure 12: Global Market Y-o-Y Growth (%) Projections by Diagnosis, 2023 to 2033 Figure 13: Global Market Attractiveness by Type, 2023 to 2033 Figure 14: Global Market Attractiveness by Diagnosis, 2023 to 2033 Figure 15: Global Market Attractiveness by Region, 2023 to 2033 Figure 16: North America Market Value (US$ Million) by Type, 2023 to 2033 Figure 17: North America Market Value (US$ Million) by Diagnosis, 2023 to 2033 Figure 18: North America Market Value (US$ Million) by Country, 2023 to 2033 Figure 19: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 20: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 21: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 22: North America Market Value (US$ Million) Analysis by Type, 2018 to 2033 Figure 23: North America Market Value Share (%) and BPS Analysis by Type, 2023 to 2033 Figure 24: North America Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033 Figure 25: North America Market Value (US$ Million) Analysis by Diagnosis, 2018 to 2033 Figure 26: North America Market Value Share (%) and BPS Analysis by Diagnosis, 2023 to 2033 Figure 27: North America Market Y-o-Y Growth (%) Projections by Diagnosis, 2023 to 2033 Figure 28: North America Market Attractiveness by Type, 2023 to 2033 Figure 29: North America Market Attractiveness by Diagnosis, 2023 to 2033 Figure 30: North America Market Attractiveness by Country, 2023 to 2033 Figure 31: Latin America Market Value (US$ Million) by Type, 2023 to 2033 Figure 32: Latin America Market Value (US$ Million) by Diagnosis, 2023 to 2033 Figure 33: Latin America Market Value (US$ Million) by Country, 2023 to 2033 Figure 34: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 35: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 36: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 37: Latin America Market Value (US$ Million) Analysis by Type, 2018 to 2033 Figure 38: Latin America Market Value Share (%) and BPS Analysis by Type, 2023 to 2033 Figure 39: Latin America Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033 Figure 40: Latin America Market Value (US$ Million) Analysis by Diagnosis, 2018 to 2033 Figure 41: Latin America Market Value Share (%) and BPS Analysis by Diagnosis, 2023 to 2033 Figure 42: Latin America Market Y-o-Y Growth (%) Projections by Diagnosis, 2023 to 2033 Figure 43: Latin America Market Attractiveness by Type, 2023 to 2033 Figure 44: Latin America Market Attractiveness by Diagnosis, 2023 to 2033 Figure 45: Latin America Market Attractiveness by Country, 2023 to 2033 Figure 46: Europe Market Value (US$ Million) by Type, 2023 to 2033 Figure 47: Europe Market Value (US$ Million) by Diagnosis, 2023 to 2033 Figure 48: Europe Market Value (US$ Million) by Country, 2023 to 2033 Figure 49: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 50: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 51: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 52: Europe Market Value (US$ Million) Analysis by Type, 2018 to 2033 Figure 53: Europe Market Value Share (%) and BPS Analysis by Type, 2023 to 2033 Figure 54: Europe Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033 Figure 55: Europe Market Value (US$ Million) Analysis by Diagnosis, 2018 to 2033 Figure 56: Europe Market Value Share (%) and BPS Analysis by Diagnosis, 2023 to 2033 Figure 57: Europe Market Y-o-Y Growth (%) Projections by Diagnosis, 2023 to 2033 Figure 58: Europe Market Attractiveness by Type, 2023 to 2033 Figure 59: Europe Market Attractiveness by Diagnosis, 2023 to 2033 Figure 60: Europe Market Attractiveness by Country, 2023 to 2033 Figure 61: South Asia Market Value (US$ Million) by Type, 2023 to 2033 Figure 62: South Asia Market Value (US$ Million) by Diagnosis, 2023 to 2033 Figure 63: South Asia Market Value (US$ Million) by Country, 2023 to 2033 Figure 64: South Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 65: South Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 66: South Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 67: South Asia Market Value (US$ Million) Analysis by Type, 2018 to 2033 Figure 68: South Asia Market Value Share (%) and BPS Analysis by Type, 2023 to 2033 Figure 69: South Asia Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033 Figure 70: South Asia Market Value (US$ Million) Analysis by Diagnosis, 2018 to 2033 Figure 71: South Asia Market Value Share (%) and BPS Analysis by Diagnosis, 2023 to 2033 Figure 72: South Asia Market Y-o-Y Growth (%) Projections by Diagnosis, 2023 to 2033 Figure 73: South Asia Market Attractiveness by Type, 2023 to 2033 Figure 74: South Asia Market Attractiveness by Diagnosis, 2023 to 2033 Figure 75: South Asia Market Attractiveness by Country, 2023 to 2033 Figure 76: East Asia Market Value (US$ Million) by Type, 2023 to 2033 Figure 77: East Asia Market Value (US$ Million) by Diagnosis, 2023 to 2033 Figure 78: East Asia Market Value (US$ Million) by Country, 2023 to 2033 Figure 79: East Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 80: East Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 81: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 82: East Asia Market Value (US$ Million) Analysis by Type, 2018 to 2033 Figure 83: East Asia Market Value Share (%) and BPS Analysis by Type, 2023 to 2033 Figure 84: East Asia Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033 Figure 85: East Asia Market Value (US$ Million) Analysis by Diagnosis, 2018 to 2033 Figure 86: East Asia Market Value Share (%) and BPS Analysis by Diagnosis, 2023 to 2033 Figure 87: East Asia Market Y-o-Y Growth (%) Projections by Diagnosis, 2023 to 2033 Figure 88: East Asia Market Attractiveness by Type, 2023 to 2033 Figure 89: East Asia Market Attractiveness by Diagnosis, 2023 to 2033 Figure 90: East Asia Market Attractiveness by Country, 2023 to 2033 Figure 91: Oceania Market Value (US$ Million) by Type, 2023 to 2033 Figure 92: Oceania Market Value (US$ Million) by Diagnosis, 2023 to 2033 Figure 93: Oceania Market Value (US$ Million) by Country, 2023 to 2033 Figure 94: Oceania Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 95: Oceania Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 96: Oceania Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 97: Oceania Market Value (US$ Million) Analysis by Type, 2018 to 2033 Figure 98: Oceania Market Value Share (%) and BPS Analysis by Type, 2023 to 2033 Figure 99: Oceania Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033 Figure 100: Oceania Market Value (US$ Million) Analysis by Diagnosis, 2018 to 2033 Figure 101: Oceania Market Value Share (%) and BPS Analysis by Diagnosis, 2023 to 2033 Figure 102: Oceania Market Y-o-Y Growth (%) Projections by Diagnosis, 2023 to 2033 Figure 103: Oceania Market Attractiveness by Type, 2023 to 2033 Figure 104: Oceania Market Attractiveness by Diagnosis, 2023 to 2033 Figure 105: Oceania Market Attractiveness by Country, 2023 to 2033 Figure 106: MEA Market Value (US$ Million) by Type, 2023 to 2033 Figure 107: MEA Market Value (US$ Million) by Diagnosis, 2023 to 2033 Figure 108: MEA Market Value (US$ Million) by Country, 2023 to 2033 Figure 109: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 110: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 111: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 112: MEA Market Value (US$ Million) Analysis by Type, 2018 to 2033 Figure 113: MEA Market Value Share (%) and BPS Analysis by Type, 2023 to 2033 Figure 114: MEA Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033 Figure 115: MEA Market Value (US$ Million) Analysis by Diagnosis, 2018 to 2033 Figure 116: MEA Market Value Share (%) and BPS Analysis by Diagnosis, 2023 to 2033 Figure 117: MEA Market Y-o-Y Growth (%) Projections by Diagnosis, 2023 to 2033 Figure 118: MEA Market Attractiveness by Type, 2023 to 2033 Figure 119: MEA Market Attractiveness by Diagnosis, 2023 to 2033 Figure 120: MEA Market Attractiveness by Country, 2023 to 2033
Need specific information?
Request CustomizationExplore Healthcare Insights
View Reports
